Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology

Abstract

A pharmacophore model identified a novel class of hLigI inhibitors to treat cancer. 36 compounds were synthesized and the identified inhibitor, compound<bold>23</bold>shown antiligase activity at IC₅₀24.9 μM by abolishing the interaction between hLigI and DNA.